144 related articles for article (PubMed ID: 10023952)
1. Cirrhosis with steatohepatitis after adjuvant tamoxifen.
Oien KA; Moffat D; Curry GW; Dickson J; Habeshaw T; Mills PR; MacSween RN
Lancet; 1999 Jan; 353(9146):36-7. PubMed ID: 10023952
[No Abstract] [Full Text] [Related]
2. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis.
Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
Lancet; 1999 May; 353(9166):1802. PubMed ID: 10348023
[No Abstract] [Full Text] [Related]
3. [Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen].
Dray X; Tainturier MH; De La Lande P; Marty O; Mallet L
Gastroenterol Clin Biol; 2000 Nov; 24(11):1122-3. PubMed ID: 11139682
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen-induced cirrhotic process.
Kotiloglu G; Aki ZS; Ozyilkan O; Kutlay L
Breast J; 2001; 7(6):442-3. PubMed ID: 11843860
[No Abstract] [Full Text] [Related]
5. Fatty liver and transaminase changes with adjuvant tamoxifen therapy.
Liu CL; Huang JK; Cheng SP; Chang YC; Lee JJ; Liu TP
Anticancer Drugs; 2006 Jul; 17(6):709-13. PubMed ID: 16917217
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen-induced fatty liver in patients with breast cancer.
Ogawa Y; Murata Y; Nishioka A; Inomata T; Yoshida S
Lancet; 1998 Mar; 351(9104):725. PubMed ID: 9504521
[No Abstract] [Full Text] [Related]
7. [A case of steatohepatitis associated with tamoxifen].
Kanda T; Yokosuka O; Chiba T; Kojima H; Fukai K; Imazeki F; Saisho H
Nihon Shokakibyo Gakkai Zasshi; 2002 Sep; 99(9):1119-21. PubMed ID: 12355903
[No Abstract] [Full Text] [Related]
8. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
[TBL] [Abstract][Full Text] [Related]
9. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S
Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen-induced transient multifocal hepatic fatty infiltration.
Cai Q; Bensen M; Greene R; Kirchner J
Am J Gastroenterol; 2000 Jan; 95(1):277-9. PubMed ID: 10638597
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic steatohepatitis.
Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
Lancet; 1999 Oct; 354(9186):1299-300. PubMed ID: 10520659
[No Abstract] [Full Text] [Related]
12. Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist.
Ahmed MH; Osman KA
Breast Cancer Res Treat; 2006 May; 97(2):223-4. PubMed ID: 16322887
[No Abstract] [Full Text] [Related]
13. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer.
Akhondi-Meybodi M; Mortazavy-Zadah MR; Hashemian Z; Moaiedi M
Arab J Gastroenterol; 2011 Mar; 12(1):34-6. PubMed ID: 21429453
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen-induced submassive hepatic necrosis.
Storen EC; Hay JE; Kaur J; Zahasky K; Hartmann L
Cancer J; 2000; 6(2):58-60. PubMed ID: 11069218
[No Abstract] [Full Text] [Related]
15. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U
BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106
[TBL] [Abstract][Full Text] [Related]
16. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy.
Nishino M; Hayakawa K; Nakamura Y; Morimoto T; Mukaihara S
AJR Am J Roentgenol; 2003 Jan; 180(1):129-34. PubMed ID: 12490491
[TBL] [Abstract][Full Text] [Related]
17. [Tamoxifen; wider indications, more frequent controls?].
Mourits MJ; van der Zee AG; Willemse PH; de Vries EG
Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1766-7. PubMed ID: 11572184
[No Abstract] [Full Text] [Related]
18. Tamoxifen-induced fatty liver disease in a Caucasian patient.
Eechoute K; Mathijssen RHJ; van Gelder T
Breast Cancer Res Treat; 2018 Aug; 171(1):243-244. PubMed ID: 29736740
[No Abstract] [Full Text] [Related]
19. Occurrence of stroke with tamoxifen in NSABP B-24.
Dignam JJ; Fisher B
Lancet; 2000 Mar; 355(9206):848-9. PubMed ID: 10711957
[No Abstract] [Full Text] [Related]
20. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance.
Elefsiniotis IS; Pantazis KD; Ilias A; Pallis L; Mariolis A; Glynou I; Kada H; Moulakakis A
Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):593-8. PubMed ID: 15167162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
